Several IDH1 inhibitor therapies currently spanning two generations have FDA approval for treatment of IDH1-mutated CCA but have yet to demonstrate significant clinical outcome improvements compared to surgical resection and platinum-based doublet chemotherapy (Fig. 3d, Supplementary Table 2)48. This evidence concerns the gene IDH1 and cholangiocarcinoma.